Dr. Avery Posey is an immunologist with training in bioinformatics, biochemistry, and molecular and developmental genetics. He completed his postdoctoral training in the Center for Cellular Immunotherapies at the University of Pennsylvania with Dr. Carl H. June investigating novel CAR T cells for solid tumors; CAR T cell costimulation, signaling and metabolism; and cancer-specific glycosylation. Dr. Posey’s work was the first to target the combination of abnormal glycosylation and tumor-associated antigens as a method to avoid off-tumor, on-target toxicities. His laboratory focuses on the development of glycan-specific adoptive cell therapies for the treatment of metastatic and advanced cancers, as well as methods to improve the efficacy and impact of current cellular therapies, including gene editing and overcoming T cell exhaustion.

1) Cancer-specific glycosylation, 2) Costimulation, metabolism and signaling of CAR T cells and other adoptive immunotherapies, 3) Gene editing of engineered T cell therapies, 4) Comparative medicine oncoimmunology